furazolidone has been researched along with Ventricular Dysfunction in 1 studies
Furazolidone: A nitrofuran derivative with antiprotozoal and antibacterial activity. Furazolidone acts by gradual inhibition of monoamine oxidase. (From Martindale, The Extra Pharmacopoeia, 30th ed, p514)
furazolidone : A member of the class of oxazolidines that is 1,3-oxazolidin-2-one in which the hydrogen attached to the nitrogen is replaced by an N-{[(5-nitro-2-furyl)methylene]amino} group. It has antibacterial and antiprotozoal properties, and is used in the treatment of giardiasis and cholera.
Ventricular Dysfunction: A condition in which HEART VENTRICLES exhibit impaired function.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Carvedilol is a non-selective beta-blocker with alpha-receptor blockade and antioxidant properties." | 5.32 | Chronic treatment with carvedilol improves ventricular function and reduces myocyte apoptosis in an animal model of heart failure. ( Doye, AA; Gwathmey, JK; Hajjar, RJ; Jabbour, G; Laste, N; Lebeche, D; Lee, MX; Okafor, CC; Perreault-Micale, C; Skiroman, K, 2003) |
| "Carvedilol is a non-selective beta-blocker with alpha-receptor blockade and antioxidant properties." | 1.32 | Chronic treatment with carvedilol improves ventricular function and reduces myocyte apoptosis in an animal model of heart failure. ( Doye, AA; Gwathmey, JK; Hajjar, RJ; Jabbour, G; Laste, N; Lebeche, D; Lee, MX; Okafor, CC; Perreault-Micale, C; Skiroman, K, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Okafor, CC | 1 |
| Perreault-Micale, C | 1 |
| Hajjar, RJ | 1 |
| Lebeche, D | 1 |
| Skiroman, K | 1 |
| Jabbour, G | 1 |
| Doye, AA | 1 |
| Lee, MX | 1 |
| Laste, N | 1 |
| Gwathmey, JK | 1 |
1 other study available for furazolidone and Ventricular Dysfunction
| Article | Year |
|---|---|
Chronic treatment with carvedilol improves ventricular function and reduces myocyte apoptosis in an animal model of heart failure.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Animals; Antioxidants; Apoptosis; Carbazo | 2003 |